Who can participate in iPrEx OLE?

All participants enrolled in the first phase of the iPrEx study will be invited to continue in the Open Label Extension. Those participants who are HIV-negative will be offered daily oral PrEP with Truvada through iPrEx OLE. Participants who choose not to take PrEP can still remain in the study and receive all the benefits of study participation. 

iPrEx participants who are HIV-positive can receive regular medical monitoring and other services through iPrEx OLE, but will not receive the study drug, which is designed to prevent HIV infection.

To learn more type your question right now by clicking here.